Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • Careers
  • Investors
  • News
    • Press Release Archive
    • Press Statements
    • Podcasts
      • The Antigen Podcast
      • Get Science Podcast
      • Diverse Perspectives Podcast
      • menopause: unmuted
      • Hemcast
    • Contact Media Relations
    • Press Kits & Downloads
      • Company Press Kit
      • Pfizer Oncology Press Kit
      • PSA Narrative
      • RA NarRAtive
      • Rare Disease Gene Therapy Press Kit
      • ATTR-Amyloidosis Press Kit
      • UC Narrative
      • Eczema Inside Out Press Kit
  • Partners
    • Discovery to Pre-candidate
      • Focus Areas
        • Therapeutic Areas
          • Internal Medicine
          • Inflammation and Immunology
          • Oncology
          • Rare Disease
          • Vaccines
        • Therapeutic Modalities and Technology Platforms
          • Drug Safety
          • Gene Therapy
          • Target Sciences
          • Precision Medicine
          • Medicinal Sciences
            • Biologics Product & Process Development
            • Biotherapeutics Discovery
            • Medicine Design
            • Small Molecule Product & Process Development
        • Emerging Science
          • DNA Damage Response
          • Microsatellite Repeat Expansions
          • Senescence
      • Partnering Models
    • Candidate Through Commercialization
      • Focus Areas
        • Internal Medicine
        • Inflammation and Immunology
        • Oncology
        • Rare Disease
        • Vaccines
        • Hospital
    • Pfizer CentreOne
    • Pfizer Ventures
      • Our portfolio

Healthcare Professionals

  • Healthcare Professionals

Connect with Us

  • Connect with Us
    • Email
    • FAQ
    • Privacy Policy (NEW)
    • YouTube
    • Twitter
    • Facebook
    • LinkedIn
    • Instagram
  • Your Health

    • Healthy Living
      • Brain & Nervous System
      • Cardiovascular Health
      • Cold & Flu
      • Digestive Health
      • Healthier Aging
      • Living Tobacco Free
      • Men’s Health
      • Mental Health
      • Nutrition & Fitness
      • Pediatric Health
      • Respiratory Health
      • Skin Health
      • Vaccines & Prevention
      • Women’s Health

    • Disease & Condition
      • Cancer
      • Cardiovascular Diseases & Conditions
      • Diabetes & Metabolic Disorders
      • Immune System Diseases & Conditions
      • Infections & Infectious Diseases
      • Neurological Diseases & Conditions
      • Menopause
      • Rare Disease
      • Vaccine-Related Conditions
      • Skin Diseases & Conditions
      • Atopic Dermatitis

    • Coronavirus disease (COVID-19)

    • Managing your health
      • Caregiving
      • Evaluating Health Information
      • Tracking Your Health
      • Your Medicines
      • Health Literacy

    • Wellness
    Hot Topics

    Maintaining Emotional Well-Being During COVID-19

    Emotional Well-Being Tips for People Living with Chronic Inflammatory Conditions During COVID-19
  • Our Science

    • Driven to Discover the cure

    • Focus Areas
      • Internal Medicine
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Anti Infectives

    • Product Pipeline

    • Clinical Trials
      • Guide to Clinical Trials
      • Find a Trial
      • Expanded Access & Compassionate Use
      • Clinical Trials in Children
      • Partnering with Pfizer
      • Trial Data & Results
      • Research Integrity & Transparency
      • Diversity in Clinical Trials

    • R&D Platforms
      • Biosimilars
      • Gene Therapy
      • Medicinal Sciences
      • Precision Medicine
      • Maternal Immunization

    • Collaboration
      • Partner with Pfizer

    • Research sites

    • Coronavirus disease (COVID-19) Scientific Resources
    HOT TOPICS

    MRNA VS. CONVENTIONAL VACCINES

    What Makes an RNA Vaccine Different From a Conventional Vaccine?
  • Our People

    • Meet The Experts
      • Scientists
      • Internal Medicine – Metabolic Disease
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Medical Professionals

    • The Journey

    • Leadership
      • Executives
      • Board Members
      • Company Fact Sheet

    • Diverse Perspectives
      • Diversity & Inclusion
      • Supplier Diversity
    HOT TOPICS

    Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron

    dr_richardson_300x170.jpg

    Working Together to Empower Women

    VizagWomen_300x170.jpg

    • Hot Topics
  • Our Purpose

    • Commitment to Global Health
      • Expanding Access
      • Strengthening Health Systems
      • Providing Disaster & Humanitarian Relief
      • Unleashing the Power of Our Colleagues
      • Highlighting Individual Voices

    • Protecting People and the Environment
      • Pfizer's Green Journey
      • Product Stewardship
      • EHS Governance
      • EHS Supply Chain
      • Key Performance Indicators
      • Health & Safety
      • Human Rights

    • Positions on Health Policies
      • Ready for Cures
      • How does Pfizer price medicines?
      • Value of Medicines
      • Policy Positions
      • Creating Cures Through Facility Investments

    • Transparency
      • Working with Health Care Professionals
      • Transparency in Grants
      • Code of Conduct
      • Corporate Compliance
      • Sales and Marketing Compliance

    • Independent Grants
      • Competitive Grants Program
      • Independent Medical Education
      • Investigator Sponsored Research
      • Quality Improvement
      • COVID-19 Vaccine Grants

    • Contributions & Partnerships
      • Healthcare Charitable Contributions
      • Lobbying & Political Contributions
    HOT TOPICS

    Pfizer Women’s Resource Group

    Media Name: IWD_Pull_up_Banner_300x170.jpg

    • Hot Topics
  • Our Products

    • Product listing

    • How drugs are made
      • Branded vs. Generic
      • Biologics & Biosimilars
      • Commitment to Quality

    • Distributors
      • Pfizer Distributors
      • Greenstone Distributors

    • Medicine Safety
      • Reporting Adverse Events
      • Making Good Treatment Choices
      • Partnering With Patients
      • Health Literacy
      • Medicine Safety Tips for Patients
      • Counterfeiting
      • Unused Medicines

    • Safety Data Sheets

    • Medical Information Contacts

    • Pfizer Global Supply
    HOT TOPICS

    Universal vs. Single Payer Healthcare

    Media Name: universal_healthcare300x170.jpg
  • Careers

    • Working Here
      • Mission & Purpose
      • Culture
      • Diversity & Inclusion
      • Career Growth & Colleague Development
      • Compensation & Benefits
      • Ensuring Corporate Responsibility
    • Search Jobs
    • Student & Early Career
      • Postdoctoral Program
      • US Summer Student Worker Program
      • Opportunities for Veterans
    • Pfizer365.com
    • Our Hiring & Recruiting Process
      • Frequently Asked Questions
      • Tips for Interviewing at Pfizer
    • Connect With Us
  • Investors

    • Investors Overview
      • Why Invest / Our Story
      • Prospective Investors
      • Fact Sheet
    • Events & Presentations
    • Financials
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Interactive Data Filings
    • Investor News
    • Stock Information
      • Historical Price Lookup
      • Investment Calculator
      • Historical Stock Chart & Data
      • Dividend & Split History
      • Stock FAQs
    • Governance
      • Board Committees and Charters
      • The Pfizer Board Policies
      • Corporate Governance FAQs
      • Contact Our Directors
    • Shareholder Services
      • Stock FAQs
      • Advisory Information
      • Cost Basis Calculator
  • News

    • Contact Media Relations
    • Podcasts
    • Press Kits & Downloads
    • Press Release Archive
    • Press Statements
  • Partners
  • Footer links

    • Footer Aside Section1
      • CAREER-SEEKERS
      • INVESTORS
      • News & Media
      • Partners
    • Footer Aside Section 2
      • Healthcare Professionals
      • Business To Business
      • Change Region
      • Sitemap
    • Footer Aside Section3
      • Twitter
      • Facebook
      • Linkedin
      • Instagram
      • Youtube
    • Footer Aside Section4
      • Contact Us
      • Terms of Use
      • Privacy Policy

Amid COVID-19 Global Pandemic, The Pfizer Foundation Helps IRC Pursue Urgent Expansion of Health Access in Humanitarian Settings

Amid COVID-19 Global Pandemic, The Pfizer Foundation Helps IRC Pursue Urgent Expansion of Health Access in Humanitarian Settings
OUR PURPOSE/ Amid COVID-19 Global Pandemic, The Pfizer Foundation Helps IRC Pursue Urgent Expansion of Health Access in Humanitarian Settings
June 18, 2020

As part of our mission of providing humanitarian aid in times of crisis, The Pfizer Foundation is proud to partner with the International Rescue Committee (IRC), an organization at work in over 40 countries and over 20 U.S. cities, helping people whose lives and livelihoods are shattered by conflict and disaster to survive, recover and gain control of their future. The IRC has decades of experience responding to urgent health situations, providing funding, and offering integrated immunization, family planning, and other basic health services that often are at risk of disruption in vulnerable communities during crises.

Now, those communities are facing the coronavirus.

Over the past few months, as the COVID-19 pandemic has spread, the IRC is seeing significant disruptions in the delivery of life-saving healthcare services in the countries where they work. This includes the direct impact of COVID-19 on under-resourced health systems and communities that have already suffered from war and humanitarian disasters, as well as the secondary threat the disease is causing to these settings’ already fragile humanitarian, security and political environments.1

Since the onset of the pandemic, early media reports detailed alarming stories about local shortages of ventilators, ill-equipped intensive care units, and lack of protective equipment. In many developing countries, those shortages existed before coronavirus. One study found that nearly half (46%) of people in South Sudan, Syria, Venezuela and Yemen lack access to even the most basic and essential health services.2

Making matters even more challenging are living conditions where weak infrastructure and overcrowding can make basic measures like social distancing or regular hand washing nearly impossible. Many refugees, Internally Displaced Persons (IDPs), migrants and other marginalized populations live in informal, overcrowded settlements. For example, the population in al-Hol camp in Syria increased seven-fold in 2019 to 68,000 people residing within a total area of just 1.82km². This makes it almost four times more densely populated than New York City, significantly increasing the risk of a COVID-19 outbreak that would spread with lightning speed.3

To support the needs of these communities’ during the COVID-19 emergency, The Pfizer Foundation is proud to support the IRC’s work to help prevent the spread of the virus through a comprehensive strategy of infection prevention and control, fever testing and contact tracing, and community engagement and education. The IRC is also continuing to treat the health needs of local host communities, bringing basic health services including immunizations, women’s health and malnutrition treatment to hard-to-reach areas, while also continuing vital livelihood services including education and economic support. 

"While COVID-19 is wreaking havoc globally, refugees and displaced populations are suffering disproportionately,” said Caroline Roan, President, The Pfizer Foundation and Vice President, Global Health & Patient Access, Pfizer Inc. “Through our longstanding partnership with the International Rescue Committee, we are confident that this new support will provide immediate health relief to some of the most vulnerable and hardest-hit communities facing the health risks of the COVID-19 pandemic.” 

The Pfizer Foundation’s work with the IRC is part of a larger commitment to humanitarian relief at home and across the globe, to help high-risk communities receive the funds, medicine, and expertise necessary to meet priority health needs. These specific efforts build on The Pfizer Foundation’s existing efforts with the IRC to strengthen healthcare systems for the world’s most vulnerable populations. For example, the IRC and The Pfizer Foundation are also working in collaboration with the Jordanian Ministry of Health to launch an innovative health delivery model to provide essential primary health services to refugees in Jordan.

“COVID-19 poses a tremendous risk to the immediate and long-term health of people in humanitarian contexts, which already have severely weakened health systems from years of conflict and instability. At the IRC, we are implementing a comprehensive response plan to save lives from the direct impact of the pandemic, and to mitigate the secondary impacts of the outbreak,” said Dr. Mesfin Teklu Tessema, Senior Direct of Health at the IRC. “The Pfizer Foundation’s support – historically but especially now – is critical to helping meet the health needs of displaced people around the world.”

“These are not normal times,” said Caroline Roan. “We know our partners and patients are relying on us to support their critical work to fight COVID-19 around the world – especially in vulnerable settings. We are committed to helping however we can and are proud of the work and commitment of the IRC.”

NOTE: The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

1,2,3 IRC Report COVID-19 Double Emergency April 2020.pdf

MORE ON COVID-19
How to stay safe and prevent the spread.

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com.

Related Hot Topics
Albert Bourla On Ensuring Equitable Access to COVID-19 Vaccines
Albert Bourla On Ensuring Equitable Access to COVID-19 Vaccines
The Facts About Pfizer and BioNTech’s COVID-19 Vaccine
The Facts About Pfizer and BioNTech’s COVID-19 Vaccine
KZOO-Vials-in-Tray-2-(1)_380X220.jpg
Distributing Our COVID-19 Vaccine to the World
Advancing Health Equity & Social Justice Through Community Investment
Advancing Health Equity & Social Justice Through Community Investment
Scientists_Image_380X220.jpg
Albert Bourla Discusses Our FDA Submission
Covid Vaccine Study - What's Next
Our COVID-19 Vaccine Study – What’s Next?
KZOO_Filling_Line_10_380X300.jpg
COVID-19 Vaccine U.S. Distribution Fact Sheet
Chronic Stress and How to Manage It
Chronic Stress and How to Manage It
Tags
COVID-19
Partnerships
Pfizer Foundation
Show
Hide

Footer menu

  • Your Health
    • Healthy Living
    • Disease Conditions
    • Manage Your Health
  • Our Science
    • Therapeutic Areas
    • Product Pipeline
    • Clinical Trials
    • R&D Platforms
    • Collaboration
    • Research SItes
  • Our People
    • Meet the Experts
    • The Journey
    • Leadership
    • Diverse Perspectives
  • Our Purpose
    • Commitment To Global Health
    • Positions on Health Policies
    • Transparency
    • Contributions & Partnerships
  • Our Products
    • Product Listing
    • How Drugs are Made
    • Distributors
    • Global Product Information Contacts

Footer aside

  • Footer Aside Section1
    • CAREER-SEEKERS
    • INVESTORS
    • News & Media
    • Partners
  • Footer Aside Section 2
    • Healthcare Professionals
    • Business To Business
    • Change Region
    • Sitemap
  • Footer Aside Section3
    • Twitter
    • Facebook
    • Linkedin
    • Instagram
    • Youtube
  • Footer Aside Section4
    • Contact Us
    • Terms of Use
    • Privacy Policy
Pfizer Logo Footer

Copyright © 2002-2021 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.